Large-cap Health Care company Eli Lilly and has logged a 1.6% change today on a trading volume of 350,689. The average volume for the stock is 3,910,466.
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. Based in Indianapolis, United States the company has 47,000 full time employees and a market cap of $703,578,112,000. Eli Lilly and currently offers its equity investors a dividend that yields 0.7% per year.
The company is now trading -17.67% away from its average analyst target price of $951.98 per share. The 27 analysts following the stock have set target prices ranging from $650.0 to $1190.0, and on average give Eli Lilly and a rating of buy.
Over the last 12 months LLY shares have declined by -15.1%, which represents a difference of -25.7% when compared to the S&P 500. The stock's 52 week high is $972.53 per share and its 52 week low is $677.09. With its net margins declining an average -7.3% over the last 6 years, Eli Lilly and declining profitability gives us reason to believe its stock price will continue to underwhelm.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2024 | 45,042,700 | 10,590,000 | 24 | 60.0 |
| 2023 | 34,124,100 | 5,240,400 | 15 | -31.82 |
| 2022 | 28,541,400 | 6,244,800 | 22 | 10.0 |
| 2021 | 28,318,400 | 5,581,700 | 20 | -20.0 |
| 2020 | 24,539,800 | 6,193,700 | 25 | -32.43 |
| 2019 | 22,319,500 | 8,318,400 | 37 |
